BofA analyst Tazeen Ahmad raised the firm’s price target on Apellis (APLS) to $29 from $26 and keeps a Neutral rating on the shares ahead of Q3 earnings, stating that on the company’s call the firm will look for color on Empaveli’s kidney disease early launch metrics.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on APLS:
- Apellis announces new data from Phase 3 VALIANT study on EMPAVELI
- Hold Rating for Apellis Pharmaceuticals Amid Limited Growth Potential and Market Challenges
- Apellis upgraded to Overweight from Equal Weight at Wells Fargo
- Cautious Outlook on Apellis Pharmaceuticals Amid Market Challenges and Financial Constraints
- Buy Rating for Apellis Pharmaceuticals: Long-Term Growth Potential Amidst Current Challenges